MSLN and mesothelioma: The lack of IHC in assessing eligibility for anti‐MSLN CAR T cell trials may be due to the presumption that MSLN‐expression is universally present and at high intensity, as reported in the earliest literature of MSLN immunostaining in mesothelioma.23, 24, 25, 26